Last-Resort drug opens door for transplant patients with rare blood clotting complication
NCT ID NCT04247906
First seen Jan 03, 2026 · Last updated May 15, 2026 · Updated 25 times
Summary
This program gives patients who have had a stem cell transplant and developed a serious blood clotting condition (HSCT-TMA) access to an experimental drug called narsoplimab. The goal is to control the disease when no other options are available. Adults and children who meet the criteria can receive treatment based on their doctor's judgment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOPOIETIC STEM CELL TRANSPLANT ASSOCIATED THROMBOTIC MICROANGIOPATHY (HSCT-TMA) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.